You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada : a long-term analysis based on the CURE trial . BACKGROUND Cardiovascular diseases account for nearly 20 % of all hospitalizations in Canada and consume 12 % of the total cost of all illnesses . With increasing trends of cardiovascular disease and increasing costs of care , development of cost-effective strategies is vital . The Clopidogrel in Unstable angina to prevent Recurrent Events ( CURE ) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid ( ASA ) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and , in addition , patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE ( PCI-CURE ) trial . OBJECTIVE To assess the cost-effectiveness of clopidogrel in the Canadian health care system . METHODS Estimates of hospitalization costs were based on the 2003 cost schedules released by the Health Funding and Costing Branch of the Alberta Health and Wellness , as well as on the Case Mix Group classification system . Life expectancy beyond the trial was estimated from the Saskatchewan Health Database . Cost-effectiveness was expressed as the incremental cost-effectiveness ratio , and bootstrap methods were used to estimate the joint distribution of costs and effectiveness . RESULTS Clopidogrel was shown to be cost-effective , with incremental cost-effectiveness ratios less than $ 10,000 per event prevented and less than $ 4,000 per life-year gained . The probability of clopidogrel resulting in cost per life-year gained of less than $ 20,000 was 0.975 for CURE patients and 0.904 for PCI-CURE patients . CONCLUSIONS The economic analysis demonstrated that clopidogrel combination therapy is not only cost-effective as antiplatelet therapy compared with ASA alone , but it is also cost-effective compared with other commonly used and openly reimbursed cardiovascular therapies in the Canadian health care system .
{"Intervention": ["ASA alone", "Clopidogrel", "clopidogrel combination therapy", "clopidogrel", "ASA", "clopidogrel plus acetylsalicylic acid ( ASA )"], "Outcome": ["cost-effectiveness ratios", "cost-effective", "cost per life-year gained", "gained ."], "Participant": ["coronary intervention", "acute coronary syndromes"]}